This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below, ##STR00001##

The present disclosure relates to 3′3′-cyclic dinucleotides having a carbocyclic nucleotide and derivatives that can modulate the activity of the STING adaptor protein.

The present invention is directed to compounds of the formulae I, II and III as shown below ##STR00001##
wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The present invention is directed to compounds of the formulae I, II and III as shown below ##STR00001##
wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The present invention relates to Compounds of Formula (I) or Formula (II): ##STR00001##
or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

To provide a chiral reagent or a salt thereof.

The chiral reagent has following chemical formula (I). In the formula (I), G.sup.1 and G.sup.2 are independently a hydrogen atom, a nitro group (—NO.sub.2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G.sup.1 and G.sup.2 taken together to form a group of formula (IV).

##STR00001##

To provide a chiral reagent or a salt thereof.

The chiral reagent has following chemical formula (I). In the formula (I), G.sup.1 and G.sup.2 are independently a hydrogen atom, a nitro group (—NO.sub.2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G.sup.1 and G.sup.2 taken together to form a group of formula (IV).

##STR00001##

Disclosed are a cyclic dinucleotide prodrug molecule, a preparation method therefor and an application thereof relating to the field of pharmaceuticals. The cyclic dinucleotide prodrug molecule has a structure shown in formula I, II, or III, can freely cross cell membranes and release cyclic dinucleotide, and has high cell activity.

##STR00001##

Disclosed are a cyclic dinucleotide prodrug molecule, a preparation method therefor and an application thereof relating to the field of pharmaceuticals. The cyclic dinucleotide prodrug molecule has a structure shown in formula I, II, or III, can freely cross cell membranes and release cyclic dinucleotide, and has high cell activity.

##STR00001##

Embodiments of the invention are directed to new polymer linked multimeric guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being activators of cGMP dependent protein kinase (PKG), and related monomeric precursors thereof. The invention is also directed to related monomeric compounds, which may also show modulating activity and/or may serve as monomeric precursors of the multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces.